Review of the cost of venous thromboembolism

Maria M Fernandez,1 Susan Hogue,1 Ronald Preblick,2 Winghan Jacqueline Kwong2 1RTI-Health Solutions, Market Access and Outcomes Strategy, Research Triangle Park, NC, 2Daiichi Sankyo, Inc., Health Economics & Outcomes Research, Parsippany, NJ, USA Background: Venous thromboembolism (VTE) is t...

Full description

Bibliographic Details
Main Authors: Fernandez MM, Hogue S, Preblick R, Kwong WJ
Format: Article
Language:English
Published: Dove Medical Press 2015-08-01
Series:ClinicoEconomics and Outcomes Research
Online Access:http://www.dovepress.com/review-of-the-cost-of-venous-thromboembolism-peer-reviewed-article-CEOR
_version_ 1818258109668261888
author Fernandez MM
Hogue S
Preblick R
Kwong WJ
author_facet Fernandez MM
Hogue S
Preblick R
Kwong WJ
author_sort Fernandez MM
collection DOAJ
description Maria M Fernandez,1 Susan Hogue,1 Ronald Preblick,2 Winghan Jacqueline Kwong2 1RTI-Health Solutions, Market Access and Outcomes Strategy, Research Triangle Park, NC, 2Daiichi Sankyo, Inc., Health Economics & Outcomes Research, Parsippany, NJ, USA Background: Venous thromboembolism (VTE) is the second most common medical complication and a cause of excess length of hospital stay. Its incidence and economic burden are expected to increase as the population ages. We reviewed the recent literature to provide updated cost estimates on VTE management. Methods: Literature search strategies were performed in PubMed, Embase, Cochrane Collaboration, Health Economic Evaluations Database, EconLit, and International Pharmaceutical Abstracts from 2003–2014. Additional studies were identified through searching bibliographies of related publications. Results: Eighteen studies were identified and are summarized in this review; of these, 13 reported data from the USA, four from Europe, and one from Canada. Three main cost estimations were identified: cost per VTE hospitalization or per VTE readmission; cost for VTE management, usually reported annually or during a specific period; and annual all-cause costs in patients with VTE, which included the treatment of complications and comorbidities. Cost estimates per VTE hospitalization were generally similar across the US studies, with a trend toward an increase over time. Cost per pulmonary embolism hospitalization increased from $5,198–$6,928 in 2000 to $8,764 in 2010. Readmission for recurrent VTE was generally more costly than the initial index event admission. Annual health plan payments for services related to VTE also increased from $10,804–$16,644 during the 1998–2004 period to an estimated average of $15,123 for a VTE event from 2008 to 2011. Lower costs for VTE hospitalizations and annualized all-cause costs were estimated in European countries and Canada. Conclusion: Costs for VTE treatment are considerable and increasing faster than general inflation for medical care services, with hospitalization costs being the primary cost driver. Readmissions for VTE are generally more costly than the initial VTE admission. Further studies evaluating the economic impact of new treatment options such as the non-vitamin K antagonist oral anticoagulants on VTE treatment are warranted. Keywords: deep vein thrombosis, pulmonary embolism, costs, pharmacoeconomics, resource utilization
first_indexed 2024-12-12T17:54:19Z
format Article
id doaj.art-c023e44b38154fa3b3d5b319e2294dad
institution Directory Open Access Journal
issn 1178-6981
language English
last_indexed 2024-12-12T17:54:19Z
publishDate 2015-08-01
publisher Dove Medical Press
record_format Article
series ClinicoEconomics and Outcomes Research
spelling doaj.art-c023e44b38154fa3b3d5b319e2294dad2022-12-22T00:16:45ZengDove Medical PressClinicoEconomics and Outcomes Research1178-69812015-08-012015default45146223434Review of the cost of venous thromboembolismFernandez MMHogue SPreblick RKwong WJMaria M Fernandez,1 Susan Hogue,1 Ronald Preblick,2 Winghan Jacqueline Kwong2 1RTI-Health Solutions, Market Access and Outcomes Strategy, Research Triangle Park, NC, 2Daiichi Sankyo, Inc., Health Economics & Outcomes Research, Parsippany, NJ, USA Background: Venous thromboembolism (VTE) is the second most common medical complication and a cause of excess length of hospital stay. Its incidence and economic burden are expected to increase as the population ages. We reviewed the recent literature to provide updated cost estimates on VTE management. Methods: Literature search strategies were performed in PubMed, Embase, Cochrane Collaboration, Health Economic Evaluations Database, EconLit, and International Pharmaceutical Abstracts from 2003–2014. Additional studies were identified through searching bibliographies of related publications. Results: Eighteen studies were identified and are summarized in this review; of these, 13 reported data from the USA, four from Europe, and one from Canada. Three main cost estimations were identified: cost per VTE hospitalization or per VTE readmission; cost for VTE management, usually reported annually or during a specific period; and annual all-cause costs in patients with VTE, which included the treatment of complications and comorbidities. Cost estimates per VTE hospitalization were generally similar across the US studies, with a trend toward an increase over time. Cost per pulmonary embolism hospitalization increased from $5,198–$6,928 in 2000 to $8,764 in 2010. Readmission for recurrent VTE was generally more costly than the initial index event admission. Annual health plan payments for services related to VTE also increased from $10,804–$16,644 during the 1998–2004 period to an estimated average of $15,123 for a VTE event from 2008 to 2011. Lower costs for VTE hospitalizations and annualized all-cause costs were estimated in European countries and Canada. Conclusion: Costs for VTE treatment are considerable and increasing faster than general inflation for medical care services, with hospitalization costs being the primary cost driver. Readmissions for VTE are generally more costly than the initial VTE admission. Further studies evaluating the economic impact of new treatment options such as the non-vitamin K antagonist oral anticoagulants on VTE treatment are warranted. Keywords: deep vein thrombosis, pulmonary embolism, costs, pharmacoeconomics, resource utilizationhttp://www.dovepress.com/review-of-the-cost-of-venous-thromboembolism-peer-reviewed-article-CEOR
spellingShingle Fernandez MM
Hogue S
Preblick R
Kwong WJ
Review of the cost of venous thromboembolism
ClinicoEconomics and Outcomes Research
title Review of the cost of venous thromboembolism
title_full Review of the cost of venous thromboembolism
title_fullStr Review of the cost of venous thromboembolism
title_full_unstemmed Review of the cost of venous thromboembolism
title_short Review of the cost of venous thromboembolism
title_sort review of the cost of venous thromboembolism
url http://www.dovepress.com/review-of-the-cost-of-venous-thromboembolism-peer-reviewed-article-CEOR
work_keys_str_mv AT fernandezmm reviewofthecostofvenousthromboembolism
AT hogues reviewofthecostofvenousthromboembolism
AT preblickr reviewofthecostofvenousthromboembolism
AT kwongwj reviewofthecostofvenousthromboembolism